Aimee Mcrae-Clark to Marijuana Abuse
This is a "connection" page, showing publications Aimee Mcrae-Clark has written about Marijuana Abuse.
Connection Strength
7.894
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.612
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.481
-
Approach bias modification for cannabis use disorder: A proof-of-principle study. J Subst Abuse Treat. 2018 04; 87:16-22.
Score: 0.473
-
Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. Am J Drug Alcohol Abuse. 2018; 44(1):47-55.
Score: 0.460
-
Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res. 2017 Mar; 249:318-320.
Score: 0.442
-
Treatment of Cannabis Use Disorder: Current Science and Future Outlook. Pharmacotherapy. 2016 05; 36(5):511-35.
Score: 0.420
-
Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016 09; 60:197-202.
Score: 0.420
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.410
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.401
-
Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. J Subst Abuse Treat. 2015 Oct; 57:70-4.
Score: 0.393
-
Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl). 2013 Aug; 228(4):623-31.
Score: 0.340
-
Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):49-58.
Score: 0.300
-
A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010 Nov-Dec; 19(6):481-9.
Score: 0.285
-
A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):132-8.
Score: 0.264
-
Characteristics of cocaine- and marijuana-dependent subjects presenting for medication treatment trials. Addict Behav. 2007 Jul; 32(7):1433-40.
Score: 0.219
-
Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict. 2006 Sep-Oct; 15(5):404.
Score: 0.215
-
Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat. 2003 Jun; 24(4):369-76.
Score: 0.172
-
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Psychol Addict Behav. 2022 Aug; 36(5):505-514.
Score: 0.150
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.143
-
The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend. 2020 07 01; 212:107993.
Score: 0.139
-
Self-reported cognition and marijuana use in older adults: Results from the national epidemiologic survey on alcohol and related conditions-III. Addict Behav. 2020 09; 108:106437.
Score: 0.138
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.134
-
Cannabis Withdrawal in Adults With Attention-Deficit/Hyperactivity Disorder. Prim Care Companion CNS Disord. 2018 Feb 22; 20(1).
Score: 0.119
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.117
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.113
-
Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug Alcohol Depend. 2017 07 01; 176:14-20.
Score: 0.113
-
Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017 Mar; 26(2):136-144.
Score: 0.111
-
Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov; 39(2):211-23.
Score: 0.094
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.081
-
Motives for using: a comparison of prescription opioid, marijuana and cocaine dependent individuals. Addict Behav. 2012 Apr; 37(4):373-8.
Score: 0.077
-
Assessment of club drug use in a treatment-seeking sample of individuals with marijuana dependence. Am J Addict. 2007 Nov-Dec; 16(6):484-7.
Score: 0.058